IMMUNOSABR | Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer
01-01-2017
-31-12-2024
Show more information
Organisation
EXOMNIS BIOTECH